Abbott’s investigational treatment for advanced Parkinson’s disease demonstrates positive results

Abbott (NYSE: ABT) announced the results from a Phase 3 trial evaluating the company's investigational compound for advanced Parkinson's disease, levodopa-carbidopa intestinal gel (LCIG).
Read the full story: Breaking World Pharma News